Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its ...

By using real-world data (RWD) and the insights derived from it, real-world evidence (RWE) earlier in research and ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

Explore how Wounded Warrior Project and advocates like Morgan Fox promote mental health awareness and support for veterans ...

Currax Pharmaceuticals expands its impactful campaigns, showcasing real patient stories to empower those battling obesity and food cravings across the U.S.

It’s a bad time to try to predict future pharmaceutical prices.

Celltrion's Avtozma IV gains FDA approval for treating cytokine release syndrome, enhancing treatment options for patients aged 2 and older.

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s ...

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.